Next Science (ASX:NXS) EV-to-EBIT : -3.47 (As of May. 03, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Next Science EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Next Science's Enterprise Value is A$80.50 Mil. Next Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.18 Mil. Therefore, Next Science's EV-to-EBIT for today is -3.47.

The historical rank and industry rank for Next Science's EV-to-EBIT or its related term are showing as below:

ASX:NXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.76 Med: -10.51 Max: -1.86
Current: -3.47

During the past 6 years, the highest EV-to-EBIT of Next Science was -1.86. The lowest was -23.76. And the median was -10.51.

ASX:NXS's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.89 vs ASX:NXS: -3.47

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Next Science's Enterprise Value for the quarter that ended in Dec. 2023 was A$86.75 Mil. Next Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.18 Mil. Next Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -26.71%.

Next Science EV-to-EBIT Historical Data

The historical data trend for Next Science's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science EV-to-EBIT Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-17.69

-13.39

-16.27

-7.02

-3.74

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial					-16.27	-	-7.02	-	-3.74

Competitive Comparison of Next Science's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Next Science's EV-to-EBIT falls into.

Next Science EV-to-EBIT Calculation

Next Science's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	80.499	/	-23.176
	=	-3.47

Next Science's current Enterprise Value is A$80.50 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Next Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.18 Mil.

Next Science (ASX:NXS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Next Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-23.176	/	86.7533
	=	-26.71 %

Next Science's Enterprise Value for the quarter that ended in Dec. 2023 was A$86.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Next Science's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-23.18 Mil.

Next Science EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Next Science's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines